Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-046613
Filing Date
2021-12-02
Accepted
2021-12-02 18:12:36
Documents
2
Period of Report
2021-12-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4091
2 EX-24 DOCUMENT attachment1.htm EX-24 4674
  Complete submission text file 0000899243-21-046613.txt   10178
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Issuer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address MONTE ROSA THERAPEUTICS, INC. 645 SUMMER STREET, SUITE 102 BOSTON MA 02210
Business Address
Jones Julian G (Reporting) CIK: 0001895356 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40522 | Film No.: 211468057